In contrast, until 2017, no personalized immuno-oncological or targeted therapies were available for the treatment of EGFR wild-type tumors, except for ALK mutation-positive tumors, which occur in approximately 4% of NSCLC cases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.